Format

Send to

Choose Destination
Clin Med Insights Blood Disord. 2017 Mar 8;10:1179545X17695233. doi: 10.1177/1179545X17695233. eCollection 2017.

Treatment of Myelofibrosis: Old and New Strategies.

Author information

1
Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy.

Abstract

Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm that is mainly characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia, hepatosplenomegaly, constitutional symptoms, leukaemic progression, and shortened survival. As such, this malignancy is still orphan of curative treatments; indeed, the only treatment that has a clearly demonstrated impact on disease progression is allogeneic haematopoietic stem cell transplantation, but only a minority of patients are eligible for such intensive therapy. However, more recently, the discovery of JAK2 mutations has also led to the development of small-molecule JAK1/2 inhibitors, the first of which, ruxolitinib, has been approved for the treatment of MF in the United States and Europe. In this article, we report on old and new therapeutic strategies that proved effective in early preclinical and clinical trials, and subsequently in the daily clinical practice, for patients with MF, particularly concerning the topics of anaemia, splenomegaly, iron overload, and allogeneic stem cell transplantation.

KEYWORDS:

JAK2 inhibitors; Myeloproliferative neoplasms; allogeneic stem cell transplantation; momelotinib; myelofibrosis; ruxolitinib

Conflict of interest statement

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center